9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [10]
In the citing paper
“All recommend SGLT2 inhibition for patients with T2DM and eGFR as low as 30 mL/min/1.73 m2, particularly if severely increased albuminuria is present.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“Major national and international organizations are rapidly updating recommendations and guidelines (Table 4) (85–88).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“In the US, the 2020 national median drug acquisition cost of GLP-1RAs ranges from $634 per month to $835 per month,27·41 although the out-of-pocket cost borne by patients varies considerably by insurance formulary and coverage.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [27]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“may reduce risk of cardiovascular events and death (35).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
BackgroundThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Items 901–958 of 958
Type 2 Diabetes Mellitus Case Study
PhD, L. S. S., & MD, S. N. K. (2022) · Wiley eBooks · doi:10.1002/9781394323128.ch14
Hussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
The impact of antidiabetic medications on COVID-19 outcomes in diabetic patients: an overview
Zarei, M., Vaighan, N. S., Shiravand, S., Samani, S. M. V., Sheikholeslami, M. A., & Roudbari, Z. (2024) · Physiology and Pharmacology · doi:10.61186/phypha.28.4.363
The effect of antiplatelet drugs on the management of cardiovascular diseases
Boralkar, R. R., Nilamwar, S. S., Mane, P. P., & Giri, A. B. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20250712
(2025) · Texila international journal of academic research · doi:10.21522/tijar.2014.12.02.art012
Tan, X., Brady, B. L., Xie, L., & Paprocki, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01741-8
“…[SGLT2i], dipeptidyl peptidase 4 inhibitor [DPP4i], thiazolidinediones [TZDs], as per American Diabetes Association guidelines at the time [30]); individuals using insulin or second-line antidiabetic agents drugs prior to liraglutide discontinuation were allowed to remain on these…”
Laursen, H. V. B., Udsen, F. W., Jensen, M. H., Vestergaard, P., & Johnsen, S. P. (2025) · medRxiv · doi:10.1101/2025.06.20.25328883
DEMİR, G. (2025) · Turkish Journal of Diabetes Nursing · doi:10.29228/tjdn.79970
Kulkarni, A. A., Purandare, S., & Navale, A. (2025) · International Journal of Science and Research (IJSR) · doi:10.21275/sr25803230213
Tahiruddin, T., Indriastuti, D., Syahrul, S., Irwan, A. M., & Pranata, S. (2025) · Nurse Media Journal of Nursing · doi:10.14710/nmjn.v15i1.58052
Huang, Y., Cai, Q.-H., Li, M., Guo, S., Dong, G., Hu, S.-Y., & Zhong, C. (2025) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-025-00961-4
Aydemir, S., Aydın, S. Ş., Altınkaya, O., Özmen, M., Çomaklı, N., & Aksakal, E. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05132-6
“Because comorbid diseases increase with age, physical activity decreases, glycemic control becomes difficult in DM patients, and adverse clinical results are seen [15].”
Bonilla-Bonilla, J. D., Chávez-Sanchéz, L., & Legorreta-Haquet, M. V. (2026) · Boletín Médico Del Hospital Infantil de México (English Edition) · doi:10.24875/bmhime.m25000084
Oral insulin delivery—Challenges and strategies
Sonia, T. A., & Sharma, C. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30272-5.00012-3
Wong, J. Y., & Nantha, Y. S. (2025) · Springer eBooks · doi:10.1007/978-981-97-7640-5_51
Burden of Hypoglycemia and Hyperglycemia in Insulin‐Treated Veterans Affairs Nursing Home Residents
Lee, A. K., Shi, Y., Lipska, K. J., & Lee, S. J. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70229 · Cited by 1
“Additionally, use of SGLT2 and GLP1 was rare (1%), as these medications had strict pre-authorization criteria in the VA during the study time period [30], which was before the new 2020 guidelines recommended SGLT2s and GLP1s as adjunctive cardio-renal protective therapy [31].”
Zhu, Y., Alvarez-Iglesias, A., Egan, A. M., Smyth, A., Newman, C., Macias, D. A., Devane, D., Dunne, F., O'Donnell, M. J., O’Shea, P. M., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113070
Wirksamkeit und Sicherheit einer oralen Diabetestherapie nach Lebertransplantation
Gierschner, V. (2021) · Gutenberg Open Science · doi:10.25358/openscience-5991
Incretin-based therapies in patients with Type 2 diabetes mellitus and renal impairment
Howse, P. M. (2023) · Memorial University Research Repository (Memorial University) · doi:10.48336/hems-sk50 · Cited by 1
Yang, C.-Y., Chen, Y.-R., Ou, H.-T., & Kuo, S. (2021) · Figshare · doi:10.6084/m9.figshare.13612565
Real, J., Vlacho, B., Ortega, E., Vallés, J. A., Mata-Cases, M., Castelblanco, E., Wittbrodt, E. T., Fenici, P., Kosiborod, M., Mauricio, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14944885
Chang, K.-C., Shao, S.-C., Kuo, S., Yang, C.-Y., Chen, H.-Y., Chan, Y.-Y., & Ou, H.-T. (2020) · Figshare · doi:10.6084/m9.figshare.13076588
Ming, J., Yu, X., Xu, X., Wang, L., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15132760
Συστημική μοντελοποίηση muti-omics δεδομένων για εύρεση μηχανισμών ανθρώπινων ασθενειών
Zareifi, D.-S. (2022) · DSpace - NTUA (National Technical University of Athens) · doi:10.26240/heal.ntua.22425
Yang, L. (2024) · D-Scholarship@Pitt (University of Pittsburgh)
Incretin-based drugs and the risk of skin cancer among patients with type 2 diabetes mellitus
Pradhan, R. (2023) · eScholarship@McGill (McGill) · doi:10.82308/19630 · Cited by 1
Luu, B. T. (2021) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
Föchterle, S. (2020) · University Library Linz repository (Johannes Kepler Universitat Linz)
Sheno, B. W., Goush, A. R., & Meshesha, M. D. (2025) · BMC Family Practice · doi:10.1186/s12875-025-03071-x
“[22] The other area which shows a significant discrepancy between physicians is the significant number of patients has off-target HgA1C where 33.3% of GPs tend not to agree with this opinion but 90% of our internists and 90.5% of our Residents agree on this idea which is in line with the Japanese…”
InfluentialLiu, J., Yang, Q., Liu, J., & Li, X. (2026) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2026.105345
Liu, B., Hannah, K. L., Nemlekar, P. M., Green, C. R., & Norman, G. J. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s574769
“For example, the ADA Standards of Care in Diabetes began recommending incretin mimetics as a first-line therapy in 2020 12 due to their improved potency and favorable cardiovascular outcomes.”
Pillai, G. S., Sinha, B. P., Sheeba, C. S., Barman, M., Sen, A. D., Natarajan, S., Anand, A., Kumar, A., Dickson, M., Deepthi, K. G., et al. (2026) · Indian Journal of Clinical and Experimental Ophthalmology · doi:10.18231/j.ijceo.9740.1771568693
New insights along the gut-liver axis in cardiometabolic disease
Witjes, J. J. (2023) · UvA-DARE (University of Amsterdam)
Campbell, I. W., Brand, K. M. G., Gottwald‐Hostalek, U., & Dettenbach, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03592-6
Gembillo, G., Visconti, L., Tranchida, V., Nardi, C., Calimeri, S., Gambuzza, M. E., Princiotto, M., Chinigò, C., Soraci, L., & Santoro, D. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i4.115058 · Cited by 2
Endokrin Sisteme Multidisipliner Yaklaşım
Gülaç, M., Bacak, İ., Metin, S., METİN, F. Ş., Nahsan, K. A. Y. A., Özdemir, M., Çelik, B., DEĞİRMEN, N., Çeliközlü, S., Altındağ, S. D., et al. (2025) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3743
Plant-based diet and type 2 diabetes
Aveland, A., Gregersen, S., & Ibsen, D. B. (2026) · Ugeskrift for Læger · doi:10.61409/v01250017
DÖNER, N. H., Yeşilbalkan, Ö. U., & Çetinkalp, Ş. (2026) · International Journal of Nursing Practice · doi:10.1111/ijn.70165
Cheng, S.-A., & Lim, J. H. (2026) · Life · doi:10.3390/life16071135
“While insulin therapy remains the cornerstone of T1DM management—as emphasized in the 2024 American Diabetes Association guidelines [2]—intensive insulin regimens frequently fail to prevent long-term complications and are inherently limited by risks of severe hypoglycemia and weight gain.”
Ponikowski, K., Kuchta, E., Wrzosek, K., Rudzińska, A., Kamizela, E., Kowalczyk, N., Kowalczyk, Z., Kowalewski, P., Udrycka, K., Szerej, M., et al. (2026) · Quality in Sport · doi:10.12775/qs.2026.62.73115
“Metformin (1,1-dimethylbiguanide hydrochloride) is a biguanide commonly used in the type 2 diabetes (T2D) management.”
Guerra, A. S. V., Córdova, M. P. A., & Proaño, J. E. G. (2026) · doi:10.23857/pc.v11i6.11977
Metformin Ameliorates Diabetes‐Associated Cognitive Dysfunction via p53/Parkin‐Mediated Mitophagy
Xu, W., Di, L., Wang, X., 苗清和, Sun, J., Zhao, R., Xie, X., He, Y., Li, X., Zhou, Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71093
Pranata, S., Cahyanti, S., Irham, L. M., Adikusuma, W., & Amukti, D. P. (2026) · The Nigerian Health Journal · doi:10.71637/tnhj.v26i2.1400
Libura, B., Lazar, M., Szkaradowski, Ł., Baranowski, S., Lewańska, J., Bogdański, K., Kruszyńska, Z., Aleshchyk, A., Adamczak, M., & Majewski, M. (2026) · Quality in Sport · doi:10.12775/qs.2026.68.74421
“First-line therapy for hyperglycaemia and insulin resistance is historically anchored by metformin [60].”
Knowledge and Attitudes Regarding Continuous Glucose Monitors as Predictors of Current Use
Gallegos, S. P., Zohn, J. H., Hutchins, A. M., Derksen, L. A., & Benton, M. J. (2026) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106261483745
Chen, T.-Y., Su, Y.-C., & Lin, Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197532
“Metformin, an oral antidiabetic drug (OAD) with a low risk of hypoglycemia, is the first-line treatment for patients with T2DM without severe CKD [9].”
Renal glycogen handling in diabetes: A narrative review of diabetic kidney disease pathogenesis
Ashok, D., Manjrekar, P., Shetty, B. C., & Sailet, S. S. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70448
Murad, A., Imran, M., Noor, Z., Lal, L., Khan, A., Ahmad, Z., Khan, J., & Basit, A. (2026) · Annual Methodological Archive Research Review
González-González, M. A., Pedrosa-Naudín, M. A., Fernández‐Lázaro, D., Planelles, I. D., Alvarez, E., & Gutiérrez‐Abejón, E. (2026) · Pharmaceuticals · doi:10.3390/ph19101607
“This finding is consistent with other studies that found CVD to be associated with higher persistence to SGLT-2is, but not to GLP-1 RAs [45].”
Khan, S., Kanwal, S. T., Raihan, M., Kashif, M., Rehana, kumar, A., Ashraf, S., & jahan, N. (2026) · Journal of Diabetes Metabolism and Endocrinology · doi:10.61336/jdme.0704.08
Atlı, B., Açıkara, Ö. B., Sarıaltın, S. Y., Yılmaz, Ö. D., & Koşar, M. (2026) · Istanbul Journal of Pharmacy · doi:10.26650/istanbuljpharm.2026.1812283
BindingDB (2024) · UC San Diego · doi:10.7270/q2251pd0
Yu, L., Zhang, Y., Sun, D., Hou, A., & Xia, F. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s646378
Khan, M. K. M., Ilyas, M. I. M., Kershan, J., Azmat, R. A. R., Izhar, A. I. A., Nasir, I. N. I., Akhunzada, M. S. A. M. S., & Khan, S. K. S. (2026) · Journal of Diabetes Metabolism and Endocrinology · doi:10.61336/jdme/.0703.17
Kunutsor, S. K., & Seidu, S. (2026) · Drugs · doi:10.1007/s40265-026-02420-z
Effect of metformin on chronic unpredictable mild stress in ovariectomized rats studen
Ozsagır, M. H. (2025) · Dspace Repository (Marmara Üniversitesi)
Lee, S., Byun, Y. S., Kim, J. W., Park, J. H., Cho, J., Kang, W. C., Yoon, H., Kim, W., Lee, S.-J., Lee, J. B., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.083811
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S98-S110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4246340431
- Cited by
- 914
- References
- 84
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 69 · 2023: 100 · 2022: 151 · 2021: 270 · 2020: 268
- FWCI
- 140.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Hypoglycemic Agents, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.